@article{56a4d360a92844f499846c59c8dfd082,
title = "Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures",
abstract = "Several pre-clinical models reveal that chronic chimeric antigen receptor (CAR) stimulation drives a dysfunctional state that mimics in vivo failure. In this protocol, we describe steps to induce T cell dysfunction by persistent and long-term stimulation of CAR-engineered T cells using antigen-expressing cancer cells in suspension cultures. We first described a validated method for manufacturing of CAR T cells, followed by a detailed method for chronic stimulation of CAR T cells and a strategy to evaluate these cells during the process of chronic stimulation. For complete details on the use and execution of this protocol, please refer to Singh et al. (2020).1",
keywords = "Biotechnology and bioengineering, Cancer, Immunology",
author = "Selli, {Mehmet Emrah} and Landmann, {Jack H.} and Corvin Arveseth and Nathan Singh",
note = "Funding Information: This work was supported by the NIH ( K08CA234470 ), the Gabrielle{\textquoteright}s Angel Foundation Cancer Research Award and Damon Runyon Clinical Investigator Award (all to N.S.), as well as the American Association of Immunology Career Re-entry Award (M.E.S.). We would like to thank Carl June, Sangya Agarwal, and Shunichiro Kuramitsu (University of Pennsylvania) for helpful discussions. Funding Information: This work was supported by the NIH (K08CA234470), the Gabrielle's Angel Foundation Cancer Research Award and Damon Runyon Clinical Investigator Award (all to N.S.), as well as the American Association of Immunology Career Re-entry Award (M.E.S.). We would like to thank Carl June, Sangya Agarwal, and Shunichiro Kuramitsu (University of Pennsylvania) for helpful discussions. M.E.S. and N.S. developed the protocol. M.E.S. and J.H.L. optimized the protocol. M.E.S. J.H.L. C.A. and N.S. wrote the protocol. N.S. holds patents related to CAR T cell therapy that are managed by the University of Pennsylvania. N.S. is a board member of Phoreus Therapeutics. M.E.S. is an employee of Wugen. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2023",
month = mar,
day = "17",
doi = "10.1016/j.xpro.2022.101954",
language = "English",
volume = "4",
journal = "STAR Protocols",
issn = "2666-1667",
number = "1",
}